Table 1.
Key Patient Characteristics by Tumor Site
| Overall (n=46) | Ovary (n=35, 76.1%) | Uterine (n=11, 23.9%) | p value a | ||||
|---|---|---|---|---|---|---|---|
| Age at diagnosis (mean ± SD) | 58.4±13.8 | 57.7±12.4 | 60.9±18.4 | ||||
| n | % | n | % | n | % | ||
| Race/ethnicity | |||||||
| White | 25 | 54.3% | 20 | 57.1% | 5 | 45.5% | |
| Asian | 14 | 30.4% | 11 | 31.4% | 3 | 27.3% | |
| Others | 7 | 15.2% | 4 | 11.4% | 3 | 27.3% | |
| Tumor stage | |||||||
| I or II | 29 | 63.0% | 21 | 60.0% | 8 | 72.7% | |
| III | 10 | 21.7% | 9 | 25.7% | 1 | 9.1% | |
| IV | 7 | 15.2% | 5 | 14.3% | 2 | 18.2% | |
| Endometriosis | |||||||
| Yes | 5 | 10.9% | 5 | 14.3% | 0 | 0.0% | |
| No | 41 | 89.1% | 30 | 85.7% | 11 | 100.0% | |
| Surgery | |||||||
| Primary surgery | 41 | 91.1% | 32 | 91.4% | 9 | 90.0% | |
| Secondary surgery | 4 | 8.9% | 3 | 8.6% | 1 | 10.0% | |
| PD-1 TILs | |||||||
| Negative/rare | 23 | 53.5% | 20 | 60.6% | 3 | 30% | |
| Elevated | 20 | 46.5% | 13 | 39.4% | 7 | 70% | 0.148 |
| PD-L1 IHC | |||||||
| ’0% | 15 | 34.9% | 14 | 42.4% | 1 | 10% | |
| More than 0% | 28 | 65.1% | 19 | 57.6% | 9 | 90% | 0.127 |
| PD-1 positive lymphocytes | |||||||
| ’0 | 23 | 51.1% | 21 | 60.0% | 2 | 20.0% | |
| More than 0 | 22 | 48.9% | 14 | 40.0% | 8 | 80.0% | 0.0351 |
| PD-L1 CPS score | |||||||
| <1 | 27 | 60.0% | 23 | 65.7% | 4 | 40.0% | |
| ≥1 | 18 | 40.0% | 12 | 34.3% | 6 | 60.0% | 0.1656 |
Abbreviations: SD: standard deviation; CRS: cytoreductive surgery; CPS: combined positive score; IHC: Immunohistochemistry; TILS: tumor infiltrating lymphocytes